Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 4/20 | 0.50 |
| ▸ | HTR2C | P28335 | 4/20 | 0.50 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | HTR2B | P41595 | 3/20 | 0.50 |
| ▸ | HTR6 | P50406 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.44 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25247830 | 0.83 | HTR1A (0.53) | HTR2AHTR2CHTR1AHTR6POLB | |
| SCHEMBL1595677 | 0.82 | POLB (0.65) | HTR2AHTR2CHTR1AHTR2BPOLB | |
| SCHEMBL31491930 | 0.82 | POLB (0.65) | HTR2AHTR2CHTR1AHTR2BPOLB | |
| SCHEMBL25293269 | 0.82 | HTR2A (0.48) | HTR2AHTR2CHTR1AHTR6KDM4E | |
| SCHEMBL3347649 | 0.80 | KDM4E (0.48) | KDM4EGAACYP3A4PDPK1CYP1A2 | |
| SCHEMBL25790762 | 0.79 | HTR1B (0.42) | HTR2AHTR2CHTR1AHTR2BHTR6 | |
| Iodomethane SCHEMBL9399948 | 0.79 | POLB (0.61) | HTR2AHTR2CHTR1AHTR2BPOLB | |
| SCHEMBL31411318 | 0.78 | MPO (0.55) | HTR2AHTR2CHTR2BSLC6A4TAAR1 | |
| SCHEMBL11086474 | 0.78 | HTR1A (0.47) | HTR2AHTR2CHTR1AHTR6KDM4E | |
| SCHEMBL29377929 | 0.78 | GSK3B (0.46) | HTR2AHTR2CHTR1AHTR2BHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735425-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2026-05-06 | — | — | EP | disclosed |
| US-20250353818-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-11-20 | — | — | US | disclosed |
| US-12428380-B2 | Compounds | Psylo Pty Ltd (AU) | 2025-09-30 | — | — | US | disclosed |
| US-20250214943-A1 | Compounds | Psylo Pty Ltd (AU) | 2025-07-03 | — | — | US | disclosed |
| US-20250163044-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-05-22 | — | — | US | disclosed |
| WO-2025000053-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2025-01-02 | — | — | WO | disclosed |
| CN-118974044-A | Compounds of formula (I) | 赛洛私人有限公司 | 2024-11-15 | — | — | CN | disclosed |
| EP-4452979-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2024-10-30 | — | — | EP | disclosed |
| WO-2023115165-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023115165-A1 | COMPOUNDS | Psylo Pty Ltd (AU) | 2023-06-29 | — | — | WO | disclosed |
| WO-2017213897-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | CEDARS-SINAI MEDICAL CENTER (US) | 2017-12-14 | — | — | WO | disclosed |
| CN-100390149-C | Indazole derivatives | KYOWA HAKKO KOGYO KK (JP) | 2008-05-28 | — | — | CN | disclosed |
| CN-1777590-A | Indazole derivatives | KYOWA HAKKO KOGYO KK (JP) | 2006-05-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214943-A1 | Compounds | NLN, SLC18A2, PYGB | HTR2A 94/4885HTR2C 23/4885HTR1A 185/4885 |
| US-12428380-B2 | Compounds | NLN, SLC18A2, PYGB | HTR2A 94/4885HTR2C 23/4885HTR1A 185/4885 |
| US-20250163044-A1 | COMPOUNDS | NLN, SLC18A2, PYGB | HTR2A 94/4885HTR2C 23/4885HTR1A 185/4885 |
| US-20250353818-A1 | Compounds | NLN, SLC18A2, PYGB | HTR2A 94/4885HTR2C 23/4885HTR1A 185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.